EICHORCondition: Cancer · Sponsor: Hoffmann-La Roche
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Colorado Cancer Center | Aurora, Colorado, United States | — |
| Yale University School Of Medicine | Trumbull, Connecticut, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | — |
| Carolina BioOncology Institute, PLCC | Huntersville, North Carolina, United States | — |
| St. Luke's Cancer Care Associates | Bethlehem, Pennsylvania, United States | — |
| University of Texas Health Sciences Center in San Antonio | San Antonio, Texas, United States | — |
| St Vincent'S Hospital | Darlinghurst, New South Wales, Australia | — |
| UZ Leuven | Leuven, Flemish Brabant, Belgium | — |
| Institut Jules Bordet | Brussels, Belgium | — |
| UZ Brussel | Brussels, Belgium | — |
| Hospital das Clinicas - UFRGS | Porto Alegre, Rio Grande do Sul, Brazil | — |
+ 68 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03768063